Japan MG registry: Chronological surveys over 10 years

Shigeaki Suzuki, Masayuki Masuda, Akiyuki Uzawa, Yuriko Nagane, Shingo Konno, Yasushi Suzuki, Tomoya Kubota, Takamichi Sugimoto, Makoto Samukawa, Genya Watanabe, Kei Ishizuchi, Hiroyuki Akamine, Yosuke Onishi, Kazuki Yoshizumi, Takafumi Uchi, Itaru Amino, Yuki Ueta, Naoya Minami, Naoki Kawaguchi, Takashi KimuraMasanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

The primary purpose of the Japanese myasthenia gravis registry (JAMG-R) has been to research and promote high-quality medical care for MG patients in Japan. We reviewed the findings of surveys performed by JAMG-R over an ~10-y period. The first goal for favorable quality of life (QOL) is a status of minimal manifestations (MM) or better with an oral prednisolone (PSL) dose of 5 mg/d or less (MM-5 mg). Early and aggressive use of nonoral fast-acting treatment together with low-dose oral PSL (the “EFT strategy”) is recommended to reduce disease severity with minimal oral steroid use so that the MM-5 mg target can be met as soon as possible. We conducted the fourth largest multicenter survey ever in 2021, obtaining detailed clinical information from 1710 consecutive MG patients all over Japan, and compared the 2021 surveys with those from 2012 and 2015. The frequency of patients treated with EFT strategies showed a gradual increase, reaching 39% of the total MG patients in the 2021 survey. The current and maximum dose of PSL and the number of days at high-dose (>20 mg/d) PSL showed decreases. Survey results indicate that as EFT strategies have spread, the percentage of patients on MM-5 mg has increased. We again confirmed that MM-5 mg was associated with favorable QOL in the 2021 survey. Recent data regarding COVID-19 suggests that it did not seriously impact the MG population in Japan; unfortunately, refractory MG, observed in 21% of patients, is still an unresolved problem.

Original languageEnglish
JournalClinical and Experimental Neuroimmunology
DOIs
Publication statusAccepted/In press - 2022

Keywords

  • Japan registry
  • early fast-acting treatment strategies
  • minimal manifestations
  • myasthenia gravis
  • myasthenia gravisCOVID-19
  • quality of life

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Japan MG registry: Chronological surveys over 10 years'. Together they form a unique fingerprint.

Cite this